ClinicalTrials.gg
CompletedNCT02418585TRANSFORM-2Updated Apr 29, 2025Results posted

A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

A Phase 3 interventional study of Esketamine and Placebo in Treatment-resistant Depression, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 5 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant — 4 open to participants now, 4 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Treatment-Resistant.

Enrollment
9th of 18
236 · median 210
Started
2015
with 4 others
Phase 3
11 of 18
2 open now
Registered
4th of 18
by date
Lead sponsor
11 of 18
Janssen Research & Development, LLC

Among the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, this one is the 9th largest by enrollment, is one of 5 that started in 2015, is one of 11 in phase 3, and was the 4th registered.

Depressive Disorder, Treatment-Resistant

448 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

4 of the 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 114 Depressive Disorder, Treatment-Resistant studies recruiting now, 26 (23%) set no upper age limit and 76 (67%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing esketamine in Depressive Disorder, Treatment-Resistant, or all of them as a file.
02

Study summary

The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine plus a new oral antidepressant or switching to a new oral antidepressant plus intranasal placebo.

Read the detailed description

This is a randomized, double-blind (neither the researchers nor the subjects know what treatment the subject is receiving), active-controlled, multicenter study (more than 1 study site) in subjects with TRD to assess the efficacy, safety, and tolerability of flexible doses of intranasal esketamine plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus intranasal placebo. The study will consist of 3 phases: Screening/Prospective Observational Phase (4-7 weeks), Double-blind Induction Phase (4-weeks), Follow-up Phase (24-weeks). Subjects who rollover into a long-term maintenance study will not participate in the Follow-up Phase. The antidepressant treatment, as well as any other ongoing medications being taken for depression at screening (including adjunctive/ augmentation therapies), will continue unchanged, at the same dosage, from the start of Week 1 through the end of Week 4 of the screening/prospective observational phase. Subjects' safety will be monitored throughout the study.

03

Conditions studied

  • Treatment-resistant Depression

Keywords

  • Treatment-resistant Depression
  • Esketamine
  • Placebo
  • Oral Antidepressant
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the time of signing the form (ICF), participant must be a man or woman 18 (or older if the minimum legal age of consent in the country in which the study is taking place is greater than [>]18) to 64 years of age, inclusive
  • At the start of the screening/prospective observational phase, participant must meet the (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) (if single-episode MDD, the duration must be greater than or equal to [>=] 2 years) or recurrent MDD, without psychotic features, based upon clinical assessment and confirmed by the Mini-International Neuropsychiatric Interview (MINI)
  • At the start of the screening/prospective observational phase, participant must have an Inventory of Depressive Symptomatology-Clinician rated ( IDS-C30) total score of greater than or equal to (>=) 34
  • At the start of the screening/prospective observational phase, participant must have had non-response (greater than or equal to [\<=25] percent [%] improvement) to ≥1 but less than or equal to (\<=) 5 (if current episode is >2 years, upper limit is applicable to only the last 2 years) oral antidepressant treatments in the current episode of depression, assessed using the Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and documented by medical history and pharmacy/prescription records, for the current episode of depression. In addition, the participant is taking a different oral antidepressant treatment (on the MGH-ATRQ) for at least the previous 2 weeks at or above the minimum therapeutic dose
  • The participant's current major depressive episode, depression symptom severity (Week 1 MADRS total score >=28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using a Site Independent Qualification Assessment

Exclusion criteria

Exclusion Criteria:

  • Participants who have previously demonstrated nonresponse of depressive symptoms to esketamine or ketamine in the current major depressive episode, to all 4 of the oral antidepressant treatment options available for the double-blind induction phase (ie, duloxetine, escitalopram, sertraline, and venlafaxine extended release [XR]) in the current major depressive episode (based on MGH-ATRQ), or an adequate course of treatment with electroconvulsive therapy (ECT) in the current major depressive episode, defined as at least 7 treatments with unilateral/bilateral ECT
  • Participant has received vagal nerve stimulation (VNS) or has received deep brain stimulation (DBS) in the current episode of depression
  • Participant has a current or prior diagnosis of a psychotic disorder or MDD with psychosis, bipolar or related disorders (confirmed by the MINI), comorbid obsessive compulsive disorder, intellectual disability (DSM-5 diagnostic codes 317, 318.0, 318.1, 318.2, 315.8, and 319), borderline personality disorder, antisocial personality disorder, histrionic personality disorder, or narcissistic personality disorder
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening/prospective observational phase, per the investigator's clinical judgment or based on the Columbia Suicide Severity Rating Scale (C-SSRS)
  • Participants with history of moderate or severe substance or alcohol use disorder according to DSM-5 criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
236 participants (actual)

Study arms

  • Experimental
    Intranasal Esketamine plus oral antidepressant

    Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase. All participants will start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg per investigator's discretion. On Days 8 and 11 the dose may be increased to 84 mg (from 56 mg), remain same, or be reduced to 56 mg (from 84 mg) per investigator's discretion. On Day 15, a dose reduction from 84 mg to 56 mg is permitted, if required for tolerability; no dose increase permitted. After Day 15, dose must remain stable (unchanged). In addition participants will simultaneously initiate a new, open-label oral antidepressant (duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.

    Drug: Esketamine · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

  • Active comparator
    Placebo plus oral antidepressant

    Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in Double-Blind Induction Phase. In addition participants will simultaneously initiate a new, open-label oral antidepressant (ie, duloxetine, escitalopram, sertraline, or venlafaxine extended release \[XR\]) on Day 1 that will be continued for the duration of Double-Blind Induction Phase.

    Drug: Placebo · Drug: Duloxetine (Oral Antidepressant) · Drug: Escitalopram (Oral antidepressant) · Drug: Sertraline (Oral Antidepressant) · Drug: Venlafaxine Extended Release (XR) (Oral Antidepressant)

Interventions

  • Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.

  • DrugPlacebo

    Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.

  • Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).

  • Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.

  • Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.

  • Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Baseline up to Day 28 of Double-blind Induction Phase

  2. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])

Secondary outcomes

  1. Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8

    A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders.

    Time frame: Day 2 up to Day 28 and Day 8 up to Day 28

  2. Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

    The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

    Time frame: Baseline up to Day 28 of Double-blind Induction phase

  3. Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

    The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])

  4. Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

    PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27).

    Time frame: Baseline up to Day 28 of Double-blind Induction phase

  5. Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

    PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])

  6. Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (\>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: At Endpoint (Double-blind Induction Phase [Day 28])

  7. Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])

    Remission was defined as participants who had a MADRS total score of less than or equal to (=\<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: At Endpoint (Double-blind Induction Phase [Day 28])

  8. Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)

    Response defined as SDS total score \<= 12 and individual item scores each \<= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

    Time frame: At Day 28 [end of Double-blind Induction Phase]

  9. Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)

    Remission defined as SDS total score \<= 6 and individual item scores each \<= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive.

    Time frame: At Day 28 (End of Double-blind Induction Phase)

  10. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

    CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])

  11. Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

    GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as "End Point" for that phase.

    Time frame: Baseline up to Endpoint (Double-blind Induction Phase [Day 28])

  12. Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)

    European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health).

    Time frame: Baseline up to End of Double-blind Induction Phase (Day 28)

  13. Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)

    EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

    Time frame: Baseline up to End of Double-blind Induction Phase (Day 28)

  14. Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)

    EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

    Time frame: Baseline up to End of Double-blind Induction Phase (Day 28)

07

Results

Posted Apr 19, 2019
Limitations and caveats
As this was a flexible-dose study, dose-response relationships could not be evaluated because direct comparisons between dose groups could not be made.

Participant flow

Double Blind (DB) Phase (4 Weeks)
Participant flow — Double Blind (DB) Phase (4 Weeks)
MilestoneIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Started116111
Safety analysis set115109
Full analysis set114109
Completed9899
Not completed1812
Withdrew: Lost to follow-up11
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject47
Withdrew: Lack of efficacy20
Withdrew: Adverse event91
Withdrew: Other01
Follow-up Phase (24 Weeks)
Participant flow — Follow-up Phase (24 Weeks)
MilestoneIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Started3452
Completed1627
Not completed1825
Withdrew: Lost to follow-up33
Withdrew: Withdrawal by subject63
Withdrew: Investigator decision617
Withdrew: Other32

Outcome measures

PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Baseline up to Day 28 of Double-blind Induction Phase
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis-21.4 ± 12.32-17.0 ± 13.88
Statistical analysis
  • Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) vs Intranasal Placebo Plus Oral AD · Mixed Model for Repeated Measures · p = =0.020 · Difference of least square (ls) means: -4.0 · 95% CI -7.31 to -0.64
PrimaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Mean · Units on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- Analysis of Covariance (ANCOVA) Analysis-19.6 ± 13.58-16.3 ± 14.24
Statistical analysis
  • Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) vs Intranasal Placebo Plus Oral AD · ANCOVA · p = =0.034 · Difference of least square (ls) means: -3.5 · 95% CI -6.67 to -0.26
SecondaryPercentage of Participants With Onset of Clinical Response on Day 2 and Day 8

A participant was defined as having a clinical response if there is at least 50 percent (%) improvement from baseline in the MADRS total score with onset by Day 2 and Day 8 that was maintained to Day 28. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Participants who did not meet such criterion or discontinue during the study before Day 28 for any reason were considered as non-responders.

Time frame:
Day 2 up to Day 28 and Day 8 up to Day 28
Reported as:
Number · Percentage of participants
Percentage of Participants With Onset of Clinical Response on Day 2 and Day 8
Percentage of participantsIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Onset of Clinical response on Day 27.94.6
Onset of Clinical response on Day 810.56.4
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

Time frame:
Baseline up to Day 28 of Double-blind Induction phase
Reported as:
Mean · Units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis-13.6 ± 8.31-9.4 ± 8.43
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

The SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Mean · Units on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis-12.5 ± 8.85-9.3 ± 8.39
SecondaryChange From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis

PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day. Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27).

Time frame:
Baseline up to Day 28 of Double-blind Induction phase
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Day 28 of Double-blind Induction Phase- MMRM Analysis-13.0 ± 6.42-10.2 ± 7.80
SecondaryChange From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis

PHQ-9 is 9-item, self-report scale assessing depressive symptoms. Each item is rated on 4-point scale (0=Not at all, 1=Several Days, 2=More than half days, 3=Nearly every day). Scale scores each of 9 symptom domains of Diagnostic and Statistical Manual of Mental Disorders, Major Depressive Disorder criteria and it has been used both as screening tool and measure of response to treatment for depression. The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. Severity of PHQ-9 categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27). The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Mean · Units on a scale
Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Patient Health Questionnaire - 9-Item Depression Module (PHQ-9) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])- ANCOVA Analysis-12.2 ± 6.87-10.1 ± 7.87
SecondaryPercentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The percentage of participants with greater than or equal to (\>=) 50 % reduction from baseline in MADRS total score was reported. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
At Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])
Percentage of participantsIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Percentage of Participants Who Achieved >=50% Reduction From Baseline in MADRS Total Score at the Endpoint (Double-blind Induction Phase [Day 28])63.449.5
SecondaryPercentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])

Remission was defined as participants who had a MADRS total score of less than or equal to (=\<) 12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
At Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])
Percentage of participantsIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Percentage of Participants in Remission (MADRS<=12) at the Endpoint (Double-blind Induction Phase [Day 28])48.230.3
SecondaryPercentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)

Response defined as SDS total score \<= 12 and individual item scores each \<= 4. SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

Time frame:
At Day 28 [end of Double-blind Induction Phase]
Reported as:
Number · Percentage of participants
Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)
Percentage of participantsIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Percentage of Participants in Response (SDS Total Score <=12 and Individual Item Scores Each <=4) at the End of 4-Week Double-blind Induction Phase (Day 28)57.039.5
SecondaryPercentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)

Remission defined as SDS total score \<= 6 and individual item scores each \<= 2. SDS is a participant reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive.

Time frame:
At Day 28 (End of Double-blind Induction Phase)
Reported as:
Number · Percentage of participants
Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)
Percentage of participantsIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Percentage of Participants in Remission (SDS Total Score <=6 and Individual Item Scores Each <=2) at the End of 4-Week Double-blind Induction Phase (Day 28)39.520.9
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time. The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Median · Units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])-2.0 (-5 to 1)-2.0 (-5 to 1)
SecondaryChange From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])

GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). The last post baseline observation during the phase was carried forward as "End Point" for that phase.

Time frame:
Baseline up to Endpoint (Double-blind Induction Phase [Day 28])
Reported as:
Mean · Units on a scale
Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in Generalized Anxiety Disorder (GAD-7) Total Score up to Endpoint (Double-blind Induction Phase [Day 28])-7.9 ± 6.12-6.8 ± 5.75
SecondaryChange From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)

European Quality of Life Group-5 Dimension-5-Level (EQ-5D-5L) is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health).

Time frame:
Baseline up to End of Double-blind Induction Phase (Day 28)
Reported as:
Mean · Units on a Scale
Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)
Units on a ScaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in EQ 5D-5L-Health Status Index to End of Double-blind Induction Phase (Day 28)0.288 ± 0.23170.231 ± 0.2506
SecondaryChange From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)

EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine).

Time frame:
Baseline up to End of Double-blind Induction Phase (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in EQ 5D-5L- European Quality of Life - Visual Analogue Scale (EQ-VAS) to End of Double-blind Induction Phase (Day 28)29.1 ± 26.3220.9 ± 26.60
SecondaryChange From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)

EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a Health Status Index (HSI). Health Status Index range is -0.148 - 0.949, is anchored at 0 (dead) and 1 (full health). EQ VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \*5. Higher score indicates worst health state.

Time frame:
Baseline up to End of Double-blind Induction Phase (Day 28)
Reported as:
Mean · Units on a scale
Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)
Units on a scaleIntranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral AD
Change From Baseline in EQ 5D-5L- Sum Score to End of Double-blind Induction Phase (Day 28)-23.2 ± 16.64-17.1 ± 19.66

Adverse events

Collected over Approximately up to 2.2 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DB Phase: Intranasal Esk + Oral AD1/115 (0.9%)1/115 (0.9%)90/115 (78.3%)
DB Phase: Oral AD + Intranasal Placebo0/109 (0%)1/109 (0.9%)53/109 (48.6%)
FU Phase: Intranasal Esk + Oral AD0/34 (0%)1/34 (2.9%)7/34 (20.6%)
FU Phase: Oral AD + Intranasal Placebo0/52 (0%)0/52 (0%)6/52 (11.5%)
Most frequent serious events
Most frequent serious events
EventDB Phase: Intranasal Esk + Oral ADDB Phase: Oral AD + Intranasal PlaceboFU Phase: Intranasal Esk + Oral ADFU Phase: Oral AD + Intranasal Placebo
Cerebral HaemorrhageNervous system disorders0/1150/1091/340/52
Vertigo PositionalEar and labyrinth disorders0/1151/1090/340/52
Multiple InjuriesInjury, poisoning and procedural complications1/1150/1090/340/52
Road Traffic AccidentInjury, poisoning and procedural complications1/1150/1090/340/52
Most frequent other events
Showing 10 of 25
Most frequent other events
EventDB Phase: Intranasal Esk + Oral ADDB Phase: Oral AD + Intranasal PlaceboFU Phase: Intranasal Esk + Oral ADFU Phase: Oral AD + Intranasal Placebo
VertigoEar and labyrinth disorders30/1153/1090/340/52
NauseaGastrointestinal disorders30/1157/1091/340/52
DissociationPsychiatric disorders30/1154/1090/340/52
DysgeusiaNervous system disorders28/11513/1090/340/52
DizzinessNervous system disorders24/1155/1091/342/52
HeadacheNervous system disorders23/11519/1092/341/52
SomnolenceNervous system disorders15/1157/1090/340/52
Vision BlurredEye disorders14/1153/1090/340/52
ParaesthesiaNervous system disorders13/1151/1091/340/52
AnxietyPsychiatric disorders12/1155/1091/341/52

Baseline characteristics

The safety analysis set included all randomized participants who received at least 1 dose of intranasal study medication or 1 dose of oral antidepressant medication during the double-blind induction phase.

Age, Categorical
Age, Categorical(Participants)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
<=18 years000
Between 18 and 65 years115109224
>=65 years000
Age, Continuous
Age, Continuous(years)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
Mean45 ± 12.5646.4 ± 11.1445.7 ± 11.89
Sex: Female, Male
Sex: Female, Male(Participants)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
Female7663139
Male394685
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
Hispanic or Latino5712
Not Hispanic or Latino10999208
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American6511
White107102209
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD)Intranasal Placebo Plus Oral ADTotal
CZECH REPUBLIC302858
GERMANY101020
POLAND201838
SPAIN9918
UNITED STATES464490
08

Study locations

51 sites
  • Birmingham, Alabama, United States
  • Orange, California, United States
  • San Rafael, California, United States
  • Maitland, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Gaithersburg, Maryland, United States
  • Boston, Massachusetts, United States
  • Philadelphia, Pennsylvania, United States
  • Dallas, Texas, United States
  • Klecany, Czechia
  • Litomerice, Czechia
  • Plzen, Czechia
  • Prague, Czechia
  • Praha 10, Czechia
  • Praha 6, Czechia
  • Prerov, Czechia
  • Berlin, Germany
  • Cham, Germany
  • Dresden, Germany
  • Gelsenkirchen, Germany
  • Halle (Saale), Germany
  • Leipzig, Germany
  • Mainz, Germany
  • Mannheim, Germany
  • Mittweida, Germany
  • Pfaffenhofen, Germany
  • Prien, Germany
  • Tübingen, Germany
  • Bialystok, Poland
  • Bydgoszcz, Poland
  • Gdansk, Poland
  • Krakow, Poland
  • Myslowice, Poland
  • Pruszkow, Poland
  • Torun, Poland
  • Tuszyn, Poland
  • Warszawa, Poland
  • Alcorcón, Spain
  • Barcelona, Spain
  • Córdoba, Spain
  • Malaga, Spain
  • Mostoles, Spain
  • Murcia, Spain
  • Palma, Spain
  • Pamplona, Spain
  • Sabadell, Spain
  • Salamanca, Spain
  • Santa Coloma De Gramanet, Spain
  • Vitoria Gasteiz, Spain
  • Vitoria-Gasteiz, Spain
09

References and documents

Publications

  • Jha MK, Williamson DJ, Magharehabed G, Turkoz I, Daly EJ, Trivedi MH. Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability. J Affect Disord. 2023 Jan 15;321:153-160. doi: 10.1016/j.jad.2022.10.020. Epub 2022 Oct 20. PubMed 36273682 ↗
  • Floden L, Hudgens S, Jamieson C, Popova V, Drevets WC, Cooper K, Singh J. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. CNS Drugs. 2022 Jun;36(6):649-658. doi: 10.1007/s40263-022-00916-2. Epub 2022 Apr 20. PubMed 35441931 ↗
  • Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P, Daly EJ, Furey ML, Fedgchin M, Popova V, Singh JB, Drevets WC. Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression. Int J Neuropsychopharmacol. 2022 Apr 19;25(4):269-279. doi: 10.1093/ijnp/pyab084. PubMed 35022754 ↗
  • Jones RR, Freeman MP, Kornstein SG, Cooper K, Daly EJ, Canuso CM, Nicholson S. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials. Arch Womens Ment Health. 2022 Apr;25(2):313-326. doi: 10.1007/s00737-021-01185-6. Epub 2022 Jan 1. PubMed 34973081 ↗
  • Dean RL, Hurducas C, Hawton K, Spyridi S, Cowen PJ, Hollingsworth S, Marquardt T, Barnes A, Smith R, McShane R, Turner EH, Cipriani A. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. Cochrane Database Syst Rev. 2021 Sep 12;9(9):CD011612. doi: 10.1002/14651858.CD011612.pub3. PubMed 34510411 ↗
  • Daly EJ, Turkoz I, Salvadore G, Fedgchin M, Ionescu DF, Starr HL, Borentain S, Trivedi MH, Thase ME, Singh JB. The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. Depress Anxiety. 2021 Nov;38(11):1120-1130. doi: 10.1002/da.23193. Epub 2021 Jul 22. PubMed 34293233 ↗
  • Turkoz I, Daly E, Singh J, Lin X, Tymofyeyev Y, Williamson D, Salvadore G, Nash AI, Macaluso M, Wilkinson ST, Nelson JC. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. J Clin Psychiatry. 2021 Jul 20;82(4):20m13800. doi: 10.4088/JCP.20m13800. PubMed 34288609 ↗
  • Doty RL, Popova V, Wylie C, Fedgchin M, Daly E, Janik A, Ochs-Ross R, Lane R, Lim P, Cooper K, Melkote R, Jamieson C, Singh J, Drevets WC. Effect of Esketamine Nasal Spray on Olfactory Function and Nasal Tolerability in Patients with Treatment-Resistant Depression: Results from Four Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Studies. CNS Drugs. 2021 Jul;35(7):781-794. doi: 10.1007/s40263-021-00826-9. Epub 2021 Jul 7. PubMed 34235612 ↗
  • Perez-Ruixo C, Rossenu S, Zannikos P, Nandy P, Singh J, Drevets WC, Perez-Ruixo JJ. Population Pharmacokinetics of Esketamine Nasal Spray and its Metabolite Noresketamine in Healthy Subjects and Patients with Treatment-Resistant Depression. Clin Pharmacokinet. 2021 Apr;60(4):501-516. doi: 10.1007/s40262-020-00953-4. Epub 2020 Oct 31. PubMed 33128208 ↗
  • Katz EG, Hough D, Doherty T, Lane R, Singh J, Levitan B. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Clin Pharmacol Ther. 2021 Feb;109(2):536-546. doi: 10.1002/cpt.2024. Epub 2020 Oct 13. PubMed 32860422 ↗
  • Saad Z, Hibar D, Fedgchin M, Popova V, Furey ML, Singh JB, Kolb H, Drevets WC, Chen G. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials. Int J Neuropsychopharmacol. 2020 Dec 3;23(9):549-558. doi: 10.1093/ijnp/pyaa030. PubMed 32367114 ↗
  • Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. 2019 Jun 1;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172. Epub 2019 May 21. PubMed 31109201 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Jun 2017, 21 months.

Results were first posted in Apr 2019, 1 year 10 months after primary completion. A results delay was requested in May 2018.

Of 24 phase 3 interventional studies under Depressive Disorder, Treatment-Resistant, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2015
First posted
Apr 16, 2015
StartActual
Aug 7, 2015
Primary completionActual
Jun 1, 2017
CompletionActual
Nov 6, 2017
Results delay requested
May 29, 2018
Results first posted
Apr 19, 2019
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02418585
Responsible party
Sponsor
First posted
Apr 16, 2015
Start date
Aug 7, 2015
Primary completion
Jun 1, 2017
Completion
Nov 6, 2017
Results posted
Apr 19, 2019
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion